All In Biotech

Free tool

FAERS Monitor: Cardiogen-82

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019414 or its brand name (Cardiogen-82, Rubidium Chloride Rb-82). Reports on generic versions are filed under their own applications.

Reports

116

Serious

38

33% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event76
  • expired product administered26
  • wrong technique in product usage process23
  • product preparation error21
  • radiation overdose8
  • off label use6
  • drug ineffective5
  • exposure to radiation5
  • therapeutic response unexpected4
  • wrong technique in drug usage process4
  • drug effect decreased3
  • intercepted product administration error3
  • product quality issue3
  • alopecia2
  • device malfunction2

Reports by year received

View as table
YearReports
20113
20121
20147
201521
20166
201813
201918
202012
202218
202311
20243
20253

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,043 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
radiation overdoseSignal831565.315235.6189,050
exposure to radiationSignal57500.03124.129,161
product preparation errorSignal21185.5125.93,672
expired product administeredSignal26141.9101.23,502
no adverse eventSignal7676.166.75,603
intercepted product administration errorSignal371.023.2143
wrong technique in product usage processSignal2320.614.3413
wrong technique in drug usage processSignal420.07.654
therapeutic response unexpectedSignal416.26.243
drug effect decreasedSignal310.13.316
device malfunction25.21.33
product quality issueSignal34.01.34
alopecia21.80.50
off label use61.20.60
drug ineffective50.70.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.